Redwood Pharma AB is a company whose mission is to develop new ophthalmic pharmaceutical therapies where there are large and unmet market needs. It has in-licensed, IntelliGel, a proprietary and patented hydrogel drug delivery platform technology that will reduce dosages, dosing-frequency and, thereby, potential systemic toxicities of active pharmaceutical ingredients. The Company’s lead development product is a new therapy to treat chronic Dry Eye Disease (DED) in post-menopausal women. With an ageing population, DED affects more and more people hindering many in their daily activities such as reading, using a computer and driving an automobile.
May 13, 2016 – Redwood Pharma genomför nyemission inför listning på AktieTorget
February 23, 2016 – Redwood Pharma raises SEK 6.6 million in private placement
February 23, 2016 – Redwood Pharma tar in SEK 6,6 miljoner genom en private placement
June 24, 2015 – Redwood Pharma licenses novel hydrogel drug delivery technology from Broda Technologies